

BIOCON GROUP

FACT SHEET

March - 2018

BIOCON LIMITED (CONSOLIDATED)**BALANCE SHEET****(Rs Cr)**

	March 31, 2018	March 31, 2017
ASSETS		
Non-current assets		
(a) Property, plant and equipment	3,630	3,553
(b) Capital work-in-progress	779	533
(c) Investment property	-	1
(d) Goodwill	26	26
(e) Other intangible assets	43	46
(f) Intangible assets under development	524	306
(g) Investments in associates and a joint venture	64	42
(h) Financial assets		
Investments	-	146
Derivative assets	111	109
Other financial assets	25	20
(i) Income-tax asset, net	127	90
(j) Deferred tax asset, net	193	197
(k) Other non-current assets	319	278
	5,841	5,347
Current assets		
(a) Inventories	723	635
(b) Financial assets		
Investments	611	1,065
Trade receivables	1,064	883
Cash and cash equivalents	501	710
Other bank balances	822	334
Derivative assets	99	106
Other financial assets	192	214
(c) Other current assets	137	100
	4,149	4,047
TOTAL	9,990	9,394
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	300	100
(b) Other equity	4,881	4,738
Equity attributable to owners of the Company	5,181	4,838
Non-controlling interests	468	376
	5,649	5,214
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,790	2,108
Derivative liability	18	6
Other financial liabilities	-	-
(b) Provisions	49	36
(c) Other non-current liabilities	342	352
	2,199	2,502
Current liabilities		
(a) Financial liabilities		
Borrowings	130	97
Trade payables	1,006	740
Derivative liability	6	6
Other financial liabilities	556	409
(b) Provisions	47	47
(c) Income tax liability, net	89	96
(d) Other current liabilities	308	283
	2,142	1,678
TOTAL	9,990	9,394

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Crores)

Particulars	FY 2018	FY 2017	Variance
INCOME			
Small molecules	1,508	1,641	-8%
Biologics	770	702	10%
Branded formulations	612	549	11%
Research services	1,423	1,193	19%
Inter-segment	(183)	(163)	13%
Revenue from operations #	4,130	3,922	5%
Other income	206	157	31%
TOTAL REVENUE	4,336	4,079	6%
EXPENDITURE			
Material & Power costs	1,825	1,611	13%
Staff costs	846	686	23%
Research & Development expenses*	216	267	-19%
Other expenses	414	378	10%
Manufacturing, staff & other expenses	3,301	2,942	12%
EBITDA	1,035	1,137	-9%
Interest & Finance charges	61	26	137%
Depreciation & Amortisation	385	277	39%
Share of profit in JV / Associate, net	(21)	(16)	31%
PBT BEFORE EXCEPTIONAL ITEM	610	850	-28%
Exceptional item, Net	-	-	-
PBT	610	850	-28%
Taxes	157	154	2%
Taxes on exceptional item	-	8	-
NET PROFIT BEFORE MINORITY INTEREST	453	688	-34%
Minority interest	81	76	6%
NET PROFIT FOR THE PERIOD	372	612	-39%
EPS Rs.	6.2	10.2	

Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers

# Licensing Income	23	145
* Gross Research & Development expenses	380	402

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 18	Q4 FY 17	Variance
<u>INCOME</u>			
Small molecules	426	395	8%
Biologics	241	163	47%
Branded formulations	149	131	14%
Research services	409	283	45%
Inter-segment	(55)	(41)	35%
Revenue from operations #	1,170	931	26%
Other income	67	43	56%
TOTAL REVENUE	1,237	974	27%
<u>EXPENDITURE</u>			
Material & Power costs	523	383	37%
Staff costs	234	178	32%
Research & Development expenses*	51	65	-22%
Other expenses	129	117	10%
Manufacturing, staff & other expenses	937	743	26%
EBITDA	300	231	30%
Interest & Finance charges	17	5	238%
Depreciation & Amortisation	95	73	31%
Share of profit in JV / Associate, net	(5)	(6)	-7%
PBT BEFORE EXCEPTIONAL ITEM	193	159	22%
Exceptional item, Net	-	-	-
PBT	193	159	22%
Taxes	41	3	1528%
Taxes on exceptional item	-	8	-
NET PROFIT BEFORE MINORITY INTEREST	152	148	3%
Minority interest	22	21	7%
NET PROFIT FOR THE PERIOD	130	127	2%
EPS Rs.	2.2	2.1	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	2	16	
* Gross Research & Development expenses	98	98	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 18	Q3 FY 18	Variance
<u>INCOME</u>			
Small molecules	426	369	15%
Biologics	241	190	27%
Branded formulations	149	156	-4%
Research services	409	388	6%
Inter-segment	(55)	(45)	24%
Revenue from operations #	1,170	1,058	11%
Other income	67	34	99%
TOTAL REVENUE	1,237	1,092	13%
<u>EXPENDITURE</u>			
Material & Power costs	523	470	11%
Staff costs	234	215	9%
Research & Development expenses*	51	53	-4%
Other expenses	129	99	30%
Manufacturing, staff & other expenses	937	837	12%
EBITDA	300	255	18%
Interest & Finance charges	17	15	15%
Depreciation & Amortisation	95	97	-2%
Share of profit in JV / Associate, net	(5)	(6)	-18%
PBT BEFORE EXCEPTIONAL ITEM	193	149	30%
Exceptional item, Net	-	-	-
PBT	193	149	30%
Taxes	41	36	13%
NET PROFIT BEFORE MINORITY INTEREST	152	113	35%
Minority interest	22	22	3%
NET PROFIT FOR THE PERIOD	130	91	43%
EPS Rs.	2.2	1.5	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	2	12	
* Gross Research & Development expenses	98	94	